DUBLIN–(BUSINESS WIRE)–The “Next-Generation
Sequencing (NGS) – Growth, Trends, and Forecast (2019 – 2024)”
report has been added to ResearchAndMarkets.com’s
offering.
The major factors, such as increasing applications of NGS, speed, cost,
and accuracy, efficient replacement for traditional technologies, and
drug discovery applications demanding NGS technology are expected to
drive the growth of the overall market.
The rapid speed, cost, and accuracy of the NGS technology help in the
growth of the market. This is attained with the help of modern DNA
sequencing technology, which has contributed to the sequencing of
complete DNA sequences of numerous types and species of life. It is also
found that NGS is significantly cheaper, quicker, and needs
significantly lesser DNA, which helps in the overall growth of the
market.
The NGS has the potential to accelerate the early detection of disorders
and the identification of pharmacogenetics markers to customize its
treatments.
There are various technological advancements in the field of medicine
that are growing at a rapid pace and has led to the development of
personalized medicine. There are a huge number of applications of
next-generation sequencing in personalized medicine. Thus, the
development of personalized medicine has opened many avenues for the
application of NGS, which could accelerate the market growth.
The current market is also facing challenges, owing to the difficulty in
management of large data and complications, associated with Big Data
management. In addition, some of the ethical issues associated with
whole-genome sequencing, coupled with the lack of awareness among
people, are pulling back the growth of the market.
Key Market Trends
Genetic Screening is the Segment Under Application that is Expected
to Grow Fastest During the Forecast Period
In genetic screening, the NGS is highly useful in identifying monogenic
diseases with locus heterogeneity, such as blindness, deafness, movement
disorders, mitochondrial disease, hereditary cancers, etc. Therefore,
NGS has a large number of varied applications through genetic screening
in multiple disorders, but their affordability and availability in
high-income and low-income countries may differ a lot. The entire
genomes are being mapped at affordable costs. Thus, steady growth is
expected in the forecast period.
The NGS is also emerging as a powerful promising pathogen-detection
method for infectious-disease diagnostics. It helps in the
identification and genomic characterization of bacteria, fungi,
parasites, and viruses, without the need for prior knowledge of a
specific pathogen, directly from clinical specimens. As the diseases
caused by infections are increasing in the less-developed countries, the
NGS-powered diagnosis of these infections has become the most promising
method to detect these infectious diseases. The NGS also has
applications in personalized medicine that has started becoming a
reality and has been under application by various biotechnology
companies.
Asia-Pacific is the Fastest-growing Market and is Expected to Follow
the Same Trend over the Forecast Period
The market studied is expected to grow at the fastest pace in
Asia-Pacific. The rising focus of the major market players is on
delivering advanced, efficient NGS technology to the developing
countries, in order to cater to the need for genomic medicines and whole
genome sequencing for personalized medicine. In addition, the increasing
adoption of NGS technology by the non-government and government bodies,
along with increased investment of the private players, is expected to
drive the Asian market.
Competitive Landscape
There are major biotech industries that are making large investments on
evolving preventive vaccines and therapeutic vaccines that can stop or
cure diseases, varying from viruses to cancers. The biotech industry,
thus, uses the NGS to develop advanced diagnostic kits, in order to
screen for pathological conditions and infectious diseases.
Key Topics Covered
1 Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Application in the Clinical Diagnosis
4.2.2 Speed, Cost, and Accuracy to Spur the Market Growth
4.2.3 Efficient Replacement for Traditional Technologies (Microarrays)
4.2.4 Drug Discovery Applications Demanding NGS Technology
4.3 Market Restraints
4.3.1 Legal and Ethical Issues
4.3.2 Interpretation of Complex Data and Lack of Skilled Professionals
4.4 Porter’s Five Forces Analysis
5 Market Segmentation
5.1 By Type of Sequencing
5.1.1 Whole Genome Sequencing
5.1.2 Targeted Resequencing
5.1.3 Whole Exome Sequencing
5.1.4 RNA Sequencing
5.1.5 CHIP Sequencing
5.1.6 De Novo Sequencing
5.1.7 Methyl Sequencing
5.2 By Product Type
5.2.1 Instruments
5.2.2 Reagents and Consumables
5.2.3 Services
5.3 By End User
5.3.1 Hospitals and Healthcare Institutions
5.3.2 Academics
5.3.3 Pharmaceutical and Biotechnology Companies
5.4 By Application
5.4.1 Drug Discovery/Personalized Medicine
5.4.2 Genetic Screening
5.4.3 Diagnostics/Infectious Diseases
5.4.4 Agriculture and Animal Research
5.4.5 Other Applications
5.5 Geography
5.5.1 North America
5.5.2 Europe
5.5.3 Asia-Pacific
5.5.4 Middle East & Africa
5.5.5 South America
6 Competitive Landscape
6.1 Company Profiles
6.1.1 Agilent Technologies
6.1.2 DNASTAR Inc.
6.1.3 F. Hoffmann-La Roche Ltd.
6.1.4 GATC Biotech AG
6.1.5 Illumina Inc.
6.1.6 Macrogen Inc.
6.1.7 Pacific Biosciences of California Inc.
6.1.8 PerkinElmer Inc.
6.1.9 Qiagen
6.1.10 Thermo Fisher Scientific Inc.
7 Market Opportunities and Future Trends
For more information about this report visit https://www.researchandmarkets.com/research/gd2kkd/nextgeneration?w=4
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Molecular
Diagnostics